Hermetica Superfood Encyclopedia
The Short Answer
Inhlaba's primary bioactive compound, andrographolide, suppresses inflammatory signaling via NF-κB pathway inhibition and blocks viral replication targets including SARS-CoV-2 3CLpro (IC50 15 µM) and the S-glycoprotein (binding energy −7.9 kcal/mol). Preclinical and in vitro data support antiviral, anti-inflammatory, and hepatoprotective activity, though large-scale human clinical trial confirmation of these effects in standardized supplement contexts remains limited.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordInhlaba benefits
Inhlaba — botanical close-up
Health Benefits
**Antiviral Activity**
Andrographolide and isoandrographolide bind key SARS-CoV-2 proteins including 3CLpro and S-glycoprotein, with isoandrographolide achieving a docking energy of −9.1 kcal/mol, inhibiting viral entry and replication in in vitro models.
**Respiratory Support**
Traditionally employed in Zulu and Asian medicine for coughs, bronchitis, and influenza, with andrographolide's anti-inflammatory actions reducing airway inflammation through NF-κB suppression and cytokine modulation.
**Anti-Inflammatory Effects**
Andrographolide downregulates the nuclear factor kappa-B (NF-κB) signaling pathway, reducing production of pro-inflammatory mediators and offering potential benefit in chronic inflammatory conditions.
**Hepatoprotection**
Bioactive diterpenoids, particularly andrographolide, modulate hepatic enzymes and protect liver cells from oxidative and toxic injury, consistent with centuries of use for viral hepatitis and cirrhosis in Ayurvedic and TCM frameworks.
**Antioxidant Properties**
Methanolic leaf extracts and isolated andrographolide reduce hydrogen peroxide-induced reactive oxygen species (ROS) in human dermal fibroblasts (HDFa cells), demonstrating cellular-level oxidative stress mitigation.
**Anticancer Potential**
Isoandrographolide and 14-acetylandrographolide exhibit tumor-suppressive properties in preclinical models, with mechanisms involving apoptosis induction and cell cycle arrest, though human data are absent.
**Antimicrobial and Anti-infective Action**
The constituent andrograpanin demonstrates anti-infective properties against bacterial and viral pathogens in laboratory settings, complementing the plant's broad traditional use as an anti-infective agent.
Origin & History
Natural habitat
Andrographis paniculata is native to South Asia, particularly India and Sri Lanka, and is widely cultivated across Southeast Asia, China, and parts of Africa where it has been adopted into local medicinal traditions. The plant thrives in moist, tropical, and subtropical environments with well-drained soils, tolerating a range of altitudes from lowland plains to hillside terrain. In southern Africa, it has been integrated into Zulu ethnobotanical practice under the regional name 'Inhlaba,' used for respiratory ailments, though the plant's commercial cultivation remains concentrated in its South Asian homeland.
“Andrographis paniculata has been documented in Ayurvedic medicine for over two millennia under the Sanskrit name 'Kalmegh,' meaning 'dark cloud,' and features prominently in the Charaka Samhita for its hepatoprotective and antipyretic properties. In Traditional Chinese Medicine, it is used as 'Chuan Xin Lian' to clear heat, resolve toxins, and treat respiratory and gastrointestinal infections, with usage recorded in the Chinese Materia Medica. The plant acquired the name 'King of Bitters' across Southeast Asia due to its intensely bitter taste attributed to andrographolide, and was notably deployed during influenza outbreaks in India in the early 20th century. In southern Africa, Zulu healers have incorporated the plant under the vernacular name 'Inhlaba,' applying preparations for respiratory ailments, demonstrating the cross-continental adoption of this herb into distinct ethnomedicinal traditions.”Traditional Medicine
Scientific Research
The existing body of evidence for Andrographis paniculata (Inhlaba) is composed predominantly of in silico molecular docking studies, in vitro cell-based assays, and preclinical animal models, with no large-scale randomized controlled trials (RCTs) reported in the available literature for the specific applications studied. Antiviral efficacy data are derived from computational binding energy calculations and cell culture IC50 measurements rather than human trials, limiting extrapolation to clinical populations. Antioxidant effects have been demonstrated in H2O2-stimulated human dermal fibroblast (HDFa) models using methanolic leaf extracts and isolated andrographolide, representing a cell-level rather than organism-level proof of concept. GC-MS phytochemical analysis has identified 14 compounds in methanolic leaf extracts including novel dodecanedioic acid, supporting chemical characterization but not clinical outcome data; overall, evidence quality warrants classification as preliminary to moderate, with further clinical investigation needed.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Zulu/African use)**
Whole plant or leaf material boiled in water and consumed as a warm tea for respiratory complaints; quantities are not standardized and vary by practitioner.
**Ethanolic/Methanolic Leaf Extract (Research Standard)**
Used in laboratory studies at concentrations achieving IC50 of 0.034–0.036 µg/mL for antiviral activity; no equivalent clinical dose established.
**Standardized Dry Extract (Commercial Supplement)**
200–400 mg per day in integrative medicine contexts, though clinical trial validation at these doses is lacking
Typically standardized to 10% andrographolide content; commonly marketed doses range from .
**Capsules/Tablets**
100–300 mg standardized extract per capsule; manufacturer recommendations typically suggest 1–2 capsules twice daily with food
Available in herbal supplement markets, usually containing .
**Optimal Harvest Timing**
Bioactive andrographolide content peaks at approximately 130 days post-cultivation during the vegetative stage and prior to flowering, making pre-flowering leaf harvest the preferred source for highest-potency preparations.
**Timing Note**
No pharmacokinetic data exist to establish whether fed or fasted administration alters absorption of andrographolide in humans.
Nutritional Profile
Andrographis paniculata leaves are not a significant dietary macronutrient source; they contain negligible protein, fat, and carbohydrate content relevant to nutrition. The primary phytochemical value resides in diterpenoid lactones — andrographolide (the dominant constituent), neoandrographolide, isoandrographolide, 14-deoxy-14,15-dehydroandrographolide, and oxoandrographolide — along with flavonoids, polyphenols, tannins, saponins, alkaloids, and steroids detectable in methanolic leaf extracts. GC-MS analysis has identified 14 phytoconstituents including novel dodecanedioic acid and fatty acid methyl esters. Andrographolide bioavailability in humans is considered limited by poor water solubility and extensive first-pass metabolism, which has driven interest in nanoformulations and lipid-based delivery systems in pharmaceutical research, though no bioavailability percentage in humans has been formally established from the current evidence base.
How It Works
Mechanism of Action
Andrographolide, the principal diterpenoid lactone in Andrographis paniculata, covalently interacts with cysteine residues in the NF-κB p50 subunit, preventing nuclear translocation and thereby suppressing transcription of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. In antiviral contexts, andrographolide and its analogs inhibit SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) with an IC50 of 15 µM and block hACE2 receptor binding and RNA-dependent RNA polymerase (RdRp) function, disrupting multiple stages of the viral lifecycle as demonstrated by molecular docking and dynamics simulations. Isoandrographolide exhibits the highest binding affinity to the S-glycoprotein (−9.1 kcal/mol), while andrographolide itself demonstrates direct antiviral IC50 of 0.034 µM in cell-based assays and an ethanolic extract IC50 of 0.036 µg/mL. Hepatoprotective effects are mediated through upregulation of phase II detoxification enzymes and modulation of cytochrome P450 activity, while antioxidant effects involve direct ROS scavenging and upregulation of endogenous antioxidant defenses.
Clinical Evidence
No human clinical trials specifically examining Inhlaba (Andrographis paniculata in the Zulu ethnomedicinal context) with defined sample sizes or effect sizes are documented in the current evidence base. The available clinical-adjacent data consist of in vitro antiviral IC50 thresholds (andrographolide IC50: 0.034 µM; ethanolic extract IC50: 0.036 µg/mL) and molecular docking binding energies that have not been validated in human pharmacokinetic or pharmacodynamic studies. Traditional use in Ayurvedic and Traditional Chinese Medicine for respiratory infections and hepatitis represents observational evidence spanning centuries, but lacks prospective controlled methodology. Confidence in clinical efficacy remains low until well-designed RCTs with prespecified primary outcomes, standardized extract formulations, and adequate sample sizes are conducted.
Safety & Interactions
Formal clinical safety data for Inhlaba preparations are absent from the current evidence base, though preclinical profiles suggest low acute toxicity at studied concentrations, with no overt cytotoxicity reported in in vitro cell models at therapeutic-range concentrations. Andrographolide is a known inhibitor and inducer of cytochrome P450 enzymes in animal models, raising theoretical concern for interactions with anticoagulants (e.g., warfarin), immunosuppressants, and antiviral medications, though specific human drug interaction data are not established. Prolonged use at high doses has been associated anecdotally with gastric discomfort and potential antifertility effects in animal studies, warranting caution in individuals attempting conception. Use during pregnancy and lactation is contraindicated based on traditional precautionary principles and preliminary animal data suggesting uterotonic activity; individuals on immunosuppressive therapy or anticoagulants should consult a healthcare provider before use.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Inhlaba (Cissus quadrangularis)KalmeghKing of BittersAndrographis paniculataChuan Xin LianGreen Chiretta
Frequently Asked Questions
What is Inhlaba used for in Zulu traditional medicine?
In Zulu ethnobotanical practice, Inhlaba (identified with Andrographis paniculata) is used primarily as a remedy for respiratory ailments including coughs, bronchitis, and influenza-like illness. Healers prepare warm decoctions from the leaves or whole plant, leveraging the herb's bitter constituents — principally andrographolide — for their perceived anti-inflammatory and anti-infective properties, consistent with parallel uses documented in Ayurvedic and Traditional Chinese Medicine.
What is the main active compound in Andrographis paniculata and what does it do?
The primary active compound is andrographolide, a diterpenoid lactone concentrated in the leaves that peaks at approximately 130 days post-cultivation. It suppresses the NF-κB inflammatory signaling pathway, inhibits viral proteins including SARS-CoV-2 3CLpro (IC50 15 µM), and has demonstrated direct antiviral IC50 of 0.034 µM in cell-based assays, alongside antioxidant and hepatoprotective activities in preclinical models.
Is there clinical trial evidence supporting Inhlaba (Andrographis paniculata) for respiratory infections?
Clinical trial evidence is currently limited; the available data are drawn from in vitro cell assays, molecular docking simulations, and animal studies rather than large-scale randomized controlled trials in humans. While traditional use across Asia and southern Africa spans centuries for respiratory conditions, and some smaller human studies on Andrographis preparations for upper respiratory infections exist in the broader literature, the specific antiviral mechanisms identified in recent research have not yet been validated in adequately powered human trials.
What is a safe dose of Andrographis paniculata supplement?
No universally validated clinical dose has been established through large-scale human trials; commercial standardized extracts (typically 10% andrographolide) are commonly marketed at 200–400 mg per day, usually divided into two doses with food. Doses used in smaller human studies for upper respiratory symptoms have ranged from 200 mg to 1200 mg per day of standardized extract, but individuals with liver conditions, those taking anticoagulants or immunosuppressants, or those who are pregnant should consult a healthcare provider before use.
Are there any side effects or drug interactions with Inhlaba (Andrographis)?
At typical supplement doses, Andrographis paniculata is generally considered low toxicity in preclinical profiles, but gastrointestinal discomfort, headache, and allergic reactions have been anecdotally reported with prolonged or high-dose use. Andrographolide interacts with cytochrome P450 enzymes in animal models, creating theoretical interactions with warfarin, immunosuppressants, and antiviral drugs; pregnancy is considered a contraindication due to animal data suggesting uterotonic activity, and those on anticoagulant therapy should exercise caution.
How does Andrographis paniculata compare to other immune-supporting herbs for viral infections?
Andrographis paniculata (Inhlaba) contains andrographolide, which has demonstrated in vitro antiviral activity against SARS-CoV-2 through inhibition of viral proteases and spike proteins, similar to mechanisms studied in other botanical antivirals like echinacea and elderberry. Unlike many traditional immune herbs that rely primarily on general immune stimulation, Andrographis shows targeted molecular binding to specific viral proteins, making it mechanistically distinct. Clinical studies on Andrographis for respiratory infections have produced more consistent positive results compared to some competing herbal options, though direct head-to-head comparative trials are limited.
Is Inhlaba (Andrographis paniculata) safe for long-term use or should it be cycled?
While Andrographis paniculata is generally well-tolerated at recommended doses, most traditional and clinical protocols suggest using it as a short-term support during acute respiratory illness rather than as a continuous daily supplement. The herb's bitter compounds and potential for gastrointestinal effects suggest that cycling—using it for 4–8 weeks followed by a break—may be a more appropriate approach than indefinite use. Consult a healthcare provider before using Inhlaba long-term, particularly if you have underlying liver or kidney conditions, as sustained intake data in vulnerable populations is limited.
What research evidence exists for Andrographis paniculata's antiviral mechanisms against modern viral threats?
In vitro studies show that andrographolide and isoandrographolide from Andrographis paniculata bind to SARS-CoV-2 viral proteins including the 3-chymotrypsin-like protease (3CLpro) and spike glycoprotein with strong docking affinities (isoandrographolide at −9.1 kcal/mol), inhibiting viral entry and replication in laboratory models. However, these molecular docking studies are preliminary and do not yet translate to proven clinical efficacy against COVID-19 in humans; clinical trials specifically validating antiviral activity in vivo are ongoing. Traditional respiratory benefits for coughs and bronchitis have more established clinical evidence than its modern antiviral applications.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w inhlaba-andrographis-paniculata curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
